Hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease by the Akt/eNOS/NO pathway

Sheng Jin1, Xu Teng1, Lin Xiao1

  • 11 Department of Physiology, Hebei Medical University, Hebei 050017, China.

Insights

Hydrogen sulfide (H2S) protects against hypertensive heart disease by activating the Akt/eNOS/NO pathway. This study shows H2S ameliorates cardiac dysfunction and remodeling in rats with hypertension.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Pharmacology

Background:

  • Reduced hydrogen sulfide (H2S) production is linked to hypertension pathogenesis.
  • The role of H2S in hypertensive heart disease remains largely unexplored.
  • Hypertensive heart disease involves cardiac remodeling and dysfunction.

Purpose of the Study:

  • To investigate the cardioprotective effects of exogenous hydrogen sulfide (NaHS) in N-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats.
  • To explore the underlying mechanisms of H2S-mediated cardioprotection, focusing on the Akt/eNOS/NO pathway and KATP channels.

Main Methods:

  • Establishment of hypertension in rats using L-NAME.
  • Administration of sodium hydrosulfide (NaHS) and glibenclamide (Gli) to assess H2S effects.
  • Evaluation of cardiac function, remodeling (histology, electron microscopy), and molecular pathways (Western blot, enzyme activity assays).

Main Results:

  • L-NAME induced hypertension, cardiac remodeling, and dysfunction, accompanied by decreased H2S and nitric oxide (NO) levels.
  • NaHS treatment increased H2S levels, improved cardiac function, and reduced cardiac remodeling.
  • H2S-mediated cardioprotection involved activation of the Akt/eNOS/NO pathway and was blocked by glibenclamide, indicating KATP channel involvement.

Conclusions:

  • Hydrogen sulfide ameliorates L-NAME-induced hypertensive heart disease, offering a novel therapeutic potential.
  • The cardioprotective effects of H2S are mediated through the activation of the Akt/eNOS/NO signaling pathway.
  • ATP-sensitive potassium (KATP) channels play a crucial role in mediating the beneficial effects of hydrogen sulfide in this model.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.1K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
392